Skip to main content
Top
Published in:

Open Access 19-03-2024 | NSCLC | Original Research

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer

Authors: Mary K. Nesline, Vivek Subbiah, Rebecca A. Previs, Kyle C. Strickland, Heidi Ko, Paul DePietro, Michael D. Biorn, Maureen Cooper, Nini Wu, Jeffrey Conroy, Sarabjot Pabla, Shengle Zhang, Zachary D. Wallen, Pratheesh Sathyan, Kamal Saini, Marcia Eisenberg, Brian Caveney, Eric A. Severson, Shakti Ramkissoon

Published in: Oncology and Therapy | Issue 2/2024

Login to get access

Abstract

Introduction

Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management of patients with non-small cell lung cancer (NSCLC). However, practice variation can affect whether all indicated biomarkers are tested. We aimed to evaluate the impact of common single-gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) test outcomes and results in NSCLC.

Methods

Oncologists who ordered SGT for guideline-recommended biomarkers in NSCLC patients were prospectively contacted (May–December 2022) and offered CGP (DNA and RNA sequencing), either following receipt of negative SGT findings, or instead of SGT for each patient. We describe SGT patterns and compare CGP completion rates, turnaround time, and recommended biomarker detection for NSCLC patients with and without prior negative SGT results.

Results

Oncologists in > 80 community practices ordered CGP for 561 NSCLC patients; 135 patients (27%) first had negative results from 30 different SGT combinations; 84% included ALK, EGFR and PD-L1, while only 3% of orders included all available SGTs for guideline-recommended genes. Among patients with negative SGT results, CGP was attempted using the same tissue specimen 90% of the time. There were also significantly more CGP order cancellations due to tissue insufficiency (17% vs. 7%), DNA sequencing failures (13% vs. 8%), and turnaround time > 14 days (62% vs. 29%) than among patients who only had CGP. Forty-six percent of patients with negative prior SGT had positive CGP results for recommended biomarkers, including targetable genomic variants in genes beyond ALK and EGFR, such as ERBB2, KRAS (non-G12C), MET (exon 14 skipping), NTRK2/3, and RET .

Conclusion

For patients with NSCLC, initial use of SGT increases subsequent CGP test cancellations, turnaround time, and the likelihood of incomplete molecular profiling for guideline-recommended biomarkers due to tissue insufficiency.
Appendix
Available only for authorised users
Literature
4.
go back to reference de Moor JS, Gray SW, Mitchell SA, Klabunde CN, Freedman AN. Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice. JCO Precis Oncol. 2020;4:620–31.CrossRef de Moor JS, Gray SW, Mitchell SA, Klabunde CN, Freedman AN. Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice. JCO Precis Oncol. 2020;4:620–31.CrossRef
5.
go back to reference Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: results of a survey of U.S. oncologists. Cancer Med. 2022;11(2):530–8.CrossRefPubMed Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: results of a survey of U.S. oncologists. Cancer Med. 2022;11(2):530–8.CrossRefPubMed
7.
go back to reference Hsiao SJ, Sireci AN, Pendrick D, Freeman C, Fernandes H, Schwartz GK, et al. Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology. JCO Precis Oncol. 2020;4:1038–48.CrossRefPubMed Hsiao SJ, Sireci AN, Pendrick D, Freeman C, Fernandes H, Schwartz GK, et al. Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology. JCO Precis Oncol. 2020;4:1038–48.CrossRefPubMed
8.
go back to reference Hall MJ, D’Avanzo P, Chertock Y, Brajuha J, Bass SB. Oncologists’ perceptions of tumor genomic profiling and the communication of test results and risks. Public Health Genomics. 2021;24(5–6):304–9.CrossRefPubMed Hall MJ, D’Avanzo P, Chertock Y, Brajuha J, Bass SB. Oncologists’ perceptions of tumor genomic profiling and the communication of test results and risks. Public Health Genomics. 2021;24(5–6):304–9.CrossRefPubMed
10.
go back to reference Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK -rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–70.CrossRefPubMedPubMedCentral Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK -rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–70.CrossRefPubMedPubMedCentral
12.
go back to reference Evangelist MC, Butrynski JE, Paschold JC, Ward PJ, Spira AI, Ali K, et al. Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. J Clin Oncol. 2023;41(16_suppl):9109–9109.CrossRef Evangelist MC, Butrynski JE, Paschold JC, Ward PJ, Spira AI, Ali K, et al. Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. J Clin Oncol. 2023;41(16_suppl):9109–9109.CrossRef
13.
go back to reference Wu N, Ge W, Quek RGW, Gleeson M, Pouliot JF, Dietz H, et al. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer. Futur Oncol. 2022;18(39):4385–97.CrossRef Wu N, Ge W, Quek RGW, Gleeson M, Pouliot JF, Dietz H, et al. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer. Futur Oncol. 2022;18(39):4385–97.CrossRef
14.
go back to reference Tomlins SA, Hovelson DH, Suga JM, Anderson DM, Koh HA, Dees EC, et al. Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. JCO Precis Oncol. 2021;5:1312–24.CrossRef Tomlins SA, Hovelson DH, Suga JM, Anderson DM, Koh HA, Dees EC, et al. Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. JCO Precis Oncol. 2021;5:1312–24.CrossRef
15.
go back to reference Diep R, Macdonald M, Cooper R, Grzegorczyk A, Rakocevic R, Chang C-F, et al. Biopsy method and needle size on success of next-generation sequencing in NSCLC: a brief report. JTO Clin Res Reports. 2023;4(4): 100497.CrossRef Diep R, Macdonald M, Cooper R, Grzegorczyk A, Rakocevic R, Chang C-F, et al. Biopsy method and needle size on success of next-generation sequencing in NSCLC: a brief report. JTO Clin Res Reports. 2023;4(4): 100497.CrossRef
17.
go back to reference Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(5):497–530.CrossRef Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(5):497–530.CrossRef
19.
go back to reference von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS ONE. 2007;2(12):1–7. von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS ONE. 2007;2(12):1–7.
20.
go back to reference Hedegaard J, Thorsen K, Lund MK, Hein A-MK, Hamilton-Dutoit SJ, Vang S, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS ONE. 2014;9(5): e98187.CrossRefPubMedPubMedCentral Hedegaard J, Thorsen K, Lund MK, Hein A-MK, Hamilton-Dutoit SJ, Vang S, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS ONE. 2014;9(5): e98187.CrossRefPubMedPubMedCentral
21.
go back to reference Locy H, Correa RJM, Autaers D, Schiettecatte A, Jonckheere J, Waelput W, et al. Overcoming the challenges of high quality RNA extraction from core needle biopsy. Biomolecules. 2021;11(5):1–19.CrossRef Locy H, Correa RJM, Autaers D, Schiettecatte A, Jonckheere J, Waelput W, et al. Overcoming the challenges of high quality RNA extraction from core needle biopsy. Biomolecules. 2021;11(5):1–19.CrossRef
22.
24.
go back to reference Roberts TJ, Kehl KL, Brooks GA, Sholl L, Wright AA, Landrum MB, et al. Practice-level variation in molecular testing and use of targeted therapy for patients with non-small cell lung cancer and colorectal cancer. JAMA Netw Open. 2023;6(4):E2310809.CrossRefPubMedPubMedCentral Roberts TJ, Kehl KL, Brooks GA, Sholl L, Wright AA, Landrum MB, et al. Practice-level variation in molecular testing and use of targeted therapy for patients with non-small cell lung cancer and colorectal cancer. JAMA Netw Open. 2023;6(4):E2310809.CrossRefPubMedPubMedCentral
25.
go back to reference Calles A, Riess JW, Brahmer JR. Checkpoint Blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ B. 2020;40:372–84.CrossRef Calles A, Riess JW, Brahmer JR. Checkpoint Blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ B. 2020;40:372–84.CrossRef
28.
go back to reference Nesline M, Pabla S, Lee YH, DePietro P, Zhang S, Klein RD, et al (2022) Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC). Am Soc Clin Oncol Nesline M, Pabla S, Lee YH, DePietro P, Zhang S, Klein RD, et al (2022) Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC). Am Soc Clin Oncol
29.
go back to reference Bhandari NR, Hess LM, He D, Peterson P. Biomarker testing, treatment, and outcomes in patients with advanced/metastatic non-small cell lung cancer using a real-world database. J Natl Compr Canc Netw. 2023;21(9):934–44.CrossRefPubMed Bhandari NR, Hess LM, He D, Peterson P. Biomarker testing, treatment, and outcomes in patients with advanced/metastatic non-small cell lung cancer using a real-world database. J Natl Compr Canc Netw. 2023;21(9):934–44.CrossRefPubMed
30.
go back to reference Stricker T, Jain N, Yu E, Ma E, Schuldt R, Wang R, et al. Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO). J Clin Oncol. 2023;41(16_Suppl):6507–6507.CrossRef Stricker T, Jain N, Yu E, Ma E, Schuldt R, Wang R, et al. Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO). J Clin Oncol. 2023;41(16_Suppl):6507–6507.CrossRef
33.
go back to reference Levy BP, Nguyen D, Shih Y-H, Gorritz M, Cai B, Caro N, et al. Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non–small-cell lung cancer (aNSCLC) in the United States. J Clin Oncol. 2023;41(16_Suppl):9117–9117.CrossRef Levy BP, Nguyen D, Shih Y-H, Gorritz M, Cai B, Caro N, et al. Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non–small-cell lung cancer (aNSCLC) in the United States. J Clin Oncol. 2023;41(16_Suppl):9117–9117.CrossRef
34.
35.
38.
go back to reference Stenzinger A, Cuffel B, Paracha N, Vail E, Garcia-Foncillas J, Goodman C, et al. Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator. Oncologist. 2023;28(5):E242–53.CrossRefPubMedPubMedCentral Stenzinger A, Cuffel B, Paracha N, Vail E, Garcia-Foncillas J, Goodman C, et al. Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator. Oncologist. 2023;28(5):E242–53.CrossRefPubMedPubMedCentral
40.
go back to reference Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, et al. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis. Lancet Reg Heal - Eur. 2024;36:100788.CrossRef Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, et al. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis. Lancet Reg Heal - Eur. 2024;36:100788.CrossRef
41.
go back to reference Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10(5):768–77.CrossRefPubMedPubMedCentral Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10(5):768–77.CrossRefPubMedPubMedCentral
42.
go back to reference Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173–80.CrossRefPubMed Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173–80.CrossRefPubMed
44.
go back to reference Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat Rev Clin Oncol. 2021;18(1):56–62.CrossRefPubMed Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR. Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat Rev Clin Oncol. 2021;18(1):56–62.CrossRefPubMed
Metadata
Title
The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
Authors
Mary K. Nesline
Vivek Subbiah
Rebecca A. Previs
Kyle C. Strickland
Heidi Ko
Paul DePietro
Michael D. Biorn
Maureen Cooper
Nini Wu
Jeffrey Conroy
Sarabjot Pabla
Shengle Zhang
Zachary D. Wallen
Pratheesh Sathyan
Kamal Saini
Marcia Eisenberg
Brian Caveney
Eric A. Severson
Shakti Ramkissoon
Publication date
19-03-2024
Publisher
Springer Healthcare
Published in
Oncology and Therapy / Issue 2/2024
Print ISSN: 2366-1070
Electronic ISSN: 2366-1089
DOI
https://doi.org/10.1007/s40487-024-00270-x

Other articles of this Issue 2/2024

Oncology and Therapy 2/2024 Go to the issue